Program
GENSCI136
A development code. Also written as “GenSci136 for injection” and “GenSci136”.
Its studies are mostly in Autoimmune Diseases, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 22 open or running | phase 2since Oct 27, 2026 | Jan 7, 2026 | Feb 7, 2027phase 1 · NCT07366866 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2026First study: phase 1 study in Autoimmune DiseasesFirst studyNCT07366866 · 56 planned · China
- Oct 27, 2026Phase 2 study in Patients With MG (gMG and oMG)Phase 2 reachedNCT07936084 · 72 planned · China
Ahead
- Feb 7, 2027Primary completion: phase 1 study in Autoimmune DiseasesNCT07366866
- Dec 2028Primary completion: phase 2 study in Patients With MG (gMG and oMG)NCT07936084
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07936084Patients With MG (gMG and oMG) · China | 2 | Not yet recruiting | Dec 2028 | 72 |
| NCT07366866Autoimmune Diseases · China | 1 | Recruiting | Feb 7, 2027 | 56 |
How it is read
Names in the registry
- “GenSci136 for injection”, 1 entry
- “GenSci136”, 1 entry
Codes read as this program: GENSCI136.
Conditions, from the studies’ own filings
- Autoimmune Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.